» Articles » PMID: 26605988

Baicalin Alleviates Silica-Induced Lung Inflammation and Fibrosis by Inhibiting the Th17 Response in C57BL/6 Mice

Overview
Journal J Nat Prod
Date 2015 Nov 26
PMID 26605988
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Silicosis is an inflammatory and fibrotic lung disease caused by inhalation of silica. Th17 cells play a key role in causing silica-induced lung inflammation and fibrosis. Baicalin, a compound isolated from the Chinese herb Huangqin, could suppress the differentiation of Th17 cells and alleviate inflammation. However, there are very few reports of the immunoregulatory mechanisms of baicalin in experimental silica-induced lung inflammation and fibrosis. In our study, mice were exposed to silica by intratracheal instillation, and in this way we established an experimental silicosis model. To elucidate the effects and mechanisms of baicalin in silica-induced inflammation and fibrosis, we used baicalin to treat the developed mouse model of silicosis. Treatment with baicalin attenuated the accumulation of inflammatory cells and led to milder pathological inflammatory and fibrotic changes in lung tissues. Baicalin affected the immunological balance between Th17 and Treg responses. Therefore, baicalin caused a decrease in Th17 cells by stimulating Treg cells and by inhibiting IL-6 and IL-23. We further demonstrated that silica-induced Th1 and Th2 immune responses were both inhibited by increased Treg activation, which was promoted by baicalin. Our findings confirmed the potential functions of baicalin in inhibiting the Th17 response and reducing silica-induced inflammation and fibrosis.

Citing Articles

Silicosis: from pathogenesis to therapeutics.

Yang B, Liu X, Peng C, Meng X, Jia Q Front Pharmacol. 2025; 16:1516200.

PMID: 39944632 PMC: 11813918. DOI: 10.3389/fphar.2025.1516200.


Global research status and trends of interactions between Traditional Chinese medicine and pulmonary fibrosis: A new dawn in treatment.

Wei B, Li H, Wang C, Hu J Heliyon. 2024; 10(14):e34592.

PMID: 39149021 PMC: 11325230. DOI: 10.1016/j.heliyon.2024.e34592.


Baicalin and lung diseases.

Sharawi Z, Ibrahim I, Abd-Alhameed E, Althagafy H, Jaber F, Harakeh S Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(3):1405-1419.

PMID: 37725153 DOI: 10.1007/s00210-023-02704-1.


Pharmacological effects of baicalin in lung diseases.

Wang D, Li Y Front Pharmacol. 2023; 14:1188202.

PMID: 37168996 PMC: 10164968. DOI: 10.3389/fphar.2023.1188202.


Baicalin alleviates silica-induced lung inflammation and fibrosis by inhibiting TLR4/NF-?B pathway in rats.

Zhang Y, Liu F, Jia Q, Zheng L, Tang Q, Sai L Physiol Res. 2023; 72(2):221-233.

PMID: 37159856 PMC: 10226396.